GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
LeMaitre to Participate in Upcoming Investor Conferences
06/11/2026
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Stifel 2026 Healthcare Conference [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
National Tirzepatide Online Telehealth Provider Ozari Health Launches Ozari Select Monthly Plan in All 50 States
06/11/2026
Ozari Select gives patients in every state, including California, month-to-month access to compounded tirzepatide at $235 and compounded semaglutide at $175, with a choice of three formulations, two named US-licensed [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
06/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
06/11/2026
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks Data support a [...]
Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
06/11/2026
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic [...]
Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
06/11/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Octobre 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/11/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
06/11/2026
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study Majority [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CEST) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Chemed Corporation Declares Quarterly Dividend of 70 Cents
06/11/2026
CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE ) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, [...]
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
06/11/2026
Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responses Data further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platform The new biomarker [...]
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
06/11/2026
Designated as one of the Top 150 abstracts submitted for the 41 st Annual Meeting of the Society for Immunotherapy of Cancer HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum